Follow Summit Therapeutics to never miss an important update.
Summit reported a loss of 26 cents per share for the third quarter, which was slightly better than the 28 cents analysts expected. As a clinical-stage biotech, the company has no revenue yet, so the focus remains entirely on its lead drug, ivonescimab. The drug recently showed it could help patients live longer than the current standard of care in trials conducted in China, which is a major hurdle for any new cancer treatment.
The most important development is a $2 billion investment from AstraZeneca that closed after the quarter ended. This gives Summit a massive cash cushion to fund expensive global trials and build a sales team if its drug is approved. With an FDA decision due on November 14, the company is now well-funded to transition from a research firm to a commercial business.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
After Summit Therapeutics reported its November results, we updated our fair value and raised our quality score to 3.6. We increased our ratings for how the business is protected from competitors and how much profit it makes on its investments. We have added the two billion dollar investment from AstraZeneca and the drug development collaborations with GSK and Daiichi Sankyo to what we track. We also adjusted our research spending projections and our expectations for when the company will need to raise more cash.
Summit is scheduled to report its quarterly results on November 9. Analysts expect the company to report no revenue and a loss of about 28 cents per share, which is typical for a biotechnology firm that is still testing its drugs and has nothing on the market yet.
The most important thing to watch is not the profit or loss, but any updates on ivonescimab. This is the company's lead drug candidate for lung cancer, and the FDA is expected to decide whether to approve it by November 14. Any commentary on the company's cash levels or its plans to hire a sales team will also be a focus for those looking at whether Summit is ready to transition from research to selling its first product.
The company reports its quarterly results today. While analysts expect a loss of about 28 cents per share on zero revenue, the financial numbers matter less right now than any updates on ivonescimab. This drug is the core of the business and is currently waiting for an FDA approval decision due by November 14.
Investors should look for updates on the drug's progress and how much cash the company has left. Since Summit is not yet selling its drug, it is spending heavily on clinical trials and preparing its sales team. Making sure it has enough money to reach the finish line without needing to sell more shares is the key thing to watch.
The company is expected to report a loss of about 28 cents per share and zero revenue, which is typical for a biotech firm still testing its main drugs. Because Summit does not have products on the market yet, the actual profit and loss numbers matter less than the update on its cash levels.
The focus for this report will be on how much cash remains to fund its expensive late-stage clinical trials. Investors will also look for any updates on ivonescimab, its lead cancer drug, as the company nears a critical FDA approval decision scheduled for mid-November.
Management consistently hits or slightly beats their own targets, showing they have a tight handle on costs while the company is still in the expensive phase of testing new drugs.
| Expectation | |
|---|---|
| EPS | $-0.36 |
| Revenue | $3M |
Follow Summit Therapeutics to get the latest and most important updates.
Follow SMMT